Healthcare / BiotechnologyKSE
$1151.00
+29.00 (+2.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-19.4B · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$104.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-126.8%
↓Gross Margin
-65.7%
↓Debt/Equity
0.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-22.1%
FCF CAGR
—
FCF margin
-72.0%
FCF / Net income
0.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $23.04B · net income $-51.85B · FCF $-16.60B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $23.04B | $23.04B | $35.72B | $40.20B | $48.72B |
| Net Income | $-51.85B | $-51.85B | $-48.54B | $-77.77B | $-38.15B |
| EBITDA | $-28.60B | $-28.60B | $-28.64B | $-63.70B | $-25.32B |
| EPS | -629.00 | -629.00 | -611.00 | -1000.00 | -492.00 |
| Gross Margin | -65.7% | -65.7% | -30.4% | -19.3% | 19.2% |
| Operating Margin | -211.6% | -211.6% | -134.9% | -120.3% | -82.3% |
| Net Margin | -225.0% | -225.0% | -135.9% | -193.4% | -78.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.81 | 0.81 | 0.32 | 0.15 | 0.11 |
| Current Ratio | 0.46 | 0.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.60B | $-16.60B | $-19.42B | $-27.40B | $-69.52B |
| Returns | |||||
| ROE | -126.8% | -126.8% | -56.7% | -69.8% | -21.0% |
| Valuation | |||||
| P/B | 2.32 | 2.32 | 2.04 | 1.93 | 3.24 |
| Growth & Yield | |||||
| Revenue Growth | -35.5% | -35.5% | -11.2% | -17.5% | — |
| EPS Growth | -2.9% | -2.9% | 38.9% | -103.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-611.00 → -629.00
Residual
-56.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.